Oncology Gene Therapy Markets

Oncology Gene Therapy: Market Forecast, Competitive Landscape and Strategic Opportunities, 2027–2031

Global forecasts by approach, vector, indication, product and route of administration, with country and regional breakouts and 15 company profiles.

Our Take

Oncology gene therapy is a CAR-T market, and it is becoming a myeloma market. We forecast the market to nearly double, from $7.1 billion in 2026 to $13.6 billion in 2031, with Carvykti alone reaching $5.1 billion. The first CAR-T products are fading, bladder cancer is the one real growth story outside CAR-T, and in vivo CAR-T, despite billions spent on acquisitions, is a story for after 2031 rather than a driver of this forecast.

Situation Analysis: what is really happening

• Myeloma overtakes lymphoma. BCMA CAR-T therapies lift myeloma revenue from $2.8 billion to $5.4 billion, making it the largest indication by 2031, and Carvykti grows to 37% of the market.
• The first generation fades. Kymriah, Abecma and Tecartus decline by about 14% a year as Breyanzi, Carvykti and bispecific antibodies take their patients.
• Bladder cancer is the breakout outside CAR-T. Adstiladrin grows six-fold to $450 million, and cretostimogene and the non-viral detalimogene are approaching regulatory filings.
• Big pharma paid early for the next generation. Gilead's $7.8 billion Arcellx deal and about $5 billion of in vivo CAR-T acquisitions buy future options, but we expect little in vivo revenue before 2031.

Company Analysis: who is positioned, who is exposed

• Johnson & Johnson / Legend Biotech: Carvykti is the market leader and its main growth engine, reaching $5.1 billion by 2031. Legend depends almost entirely on it.
• Bristol Myers Squibb: Breyanzi is the fastest-growing CD19 CAR-T, while Abecma loses share in myeloma. The Orbital acquisition adds an in vivo platform.
• Gilead (Kite): Yescarta and Tecartus are declining, so its outlook depends on anito-cel, with an FDA decision due in December 2026.
• Ferring: Adstiladrin leads bladder cancer gene therapy, but competition arrives from 2027.
• CG Oncology: Cretostimogene's 75.5% complete response rate makes it the leading bladder challenger, with its filing due to complete in the fourth quarter of 2026.
• Replimune: RP1's accelerated approval after two rejections is the test of whether oncolytic viruses can succeed commercially.

Plus 9 more company profiles covering big pharma buyers, in vivo CAR-T developers and emerging cell therapy companies.

Questions this report answers

• How fast will oncology gene therapy grow, and which products drive it?
• When does multiple myeloma overtake lymphoma as the largest CAR-T market?
• How quickly will the first CAR-T products lose share to Breyanzi, Carvykti and bispecific antibodies?
• How big can bladder cancer gene therapy become, and who will lead it?
• When will in vivo and allogeneic CAR-T generate real revenue?
• How do cost and manufacturing capacity limit CAR-T uptake?

What’s inside

• 171 pages, 23 chapters
• 15 company profiles with technology, pipeline, strategy and risks
• Forecasts 2027–2031 from a 2026 base (actual) year, by approach, vector, indication, product and route of administration, for 14 countries and regions
• Approved product registry and 2025 sales benchmarks
• Clinical pipeline, manufacturing and supply chain, regulation and reimbursement, and a China ecosystem chapter
• Delivered as 3 files: full report PDF, Situation Analysis PDF, and Excel workbook of all charts and tables
• Download the Table of Contents (PDF)

Who buys this report

• Business development and licensing teams: find acquisition and in-licensing candidates and track next-generation platforms.
• Investors and equity analysts: model CAR-T share shifts and the timing of next-generation approaches.
• Cell and gene therapy developers: choose the indications, targets and delivery approaches with the most room to grow.
• Manufacturers and suppliers: size vector and manufacturing demand by approach and vector.

Licences and support

Your order is delivered to your inbox immediately. Every licence includes unlimited questions to the analyst and custom data breakouts, including any country not shown. Single User, Five User and Enterprise licences contain the same report; they differ only in how many people may use it.

About the author

Greg Powell, B.Sc., M.B.A., has worked in laboratory testing and management for more than 20 years, with executive training at Harvard Business School and the Burke Institute.